N-desethyl isotonitazene detected in polydrug users admitted to hospital in Birmingham, United Kingdom
Pucci, Mark Singh Jutley, Gurpreet Looms, Jonathan Ford, Loretta
Pucci, Mark
Singh Jutley, Gurpreet
Looms, Jonathan
Ford, Loretta
Citations
Altmetric:
Affiliation
Sandwell and West Birmingham NHS Trust
Other Contributors
Publication date
2024-02-14
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Nitazenes are potent synthetic opioids and N-desethyl isotonitazene, a metabolite of isotonitazene, has emerged as a drug in its own right. Methods: This is an observational case series of patients with suspected or declared substance use who were admitted to hospitals in the Sandwell and West Birmingham National Health Service Trust between July and October 2023. All patients were found on toxicological screening to have been exposed to N-desethyl isotonitazene. Results: Twenty presentations involving 19 patients who tested positive for N-desethyl isotonitazene were included in the study. In 19 presentations, multiple substances were detected on toxicological screening. The number of patients testing positive for other substances were: 19 for cocaine and its main metabolite benzoylecgonine, 13 for morphine, 11 for the heroin-specific metabolite 6-monoacetylmorphine, ten for xylazine, eight for gabapentinoids (pregabalin and/or gabapentin), seven for methadone and/or the metabolite, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine, six for benzodiazepines and five for the synthetic cannabinoid MDMB-4en-PINACA. Only one patient had no other substances detected apart from N-desethyl isotonitazene. This patient presented with coma, miosis, bradypnoea and hypercapnia and responded to naloxone. In this cohort, the median concentration of N-desethyl isotonitazene was 1.53 µg/L (n = 14; range 0.59-5.48) in whole blood and 27.75 µg/L (n = 16; range 0.51-91.53) in urine. Discussion: The majority of the patients in this cohort presented with features typical of an opioid overdose, which is unsurprising as they were all experienced users of diamorphine. Although these features are also consistent with the known effects of N-desethyl isotonitazene, in only one case is it possible to attribute the patient's features to N-desethyl isotonitazene toxicity alone. Conclusions: This case series highlights the need for toxicovigilance in the illicit drug market as patterns of substance misuse evolve and novel psychoactive substances continue to emerge.
Citation
Pucci M, Singh Jutley G, Looms J, Ford L. N-desethyl isotonitazene detected in polydrug users admitted to hospital in Birmingham, United Kingdom. Clin Toxicol (Phila). 2024 Feb 14:1-7. doi: 10.1080/15563650.2024.2309321
Type
Article